论文部分内容阅读
目的：研究活脑灵治疗脑血管疾病后遗症的临床疗效及安全性。方法：选用３１例确诊为脑血管疾病（包括原发病为脑出血及脑梗塞）后遗症的患者，于活脑灵治疗前后分别观察其神经功能缺损程度、评分改变情况。结果：活脑灵治疗１５ｄ后，少数病例有所改善，但神经功能缺损程度总评分变化不显著（Ｐ＞０．０５），而治疗３０ｄ后，神经功能缺损程度总评分显著减少（Ｐ＜０．０５）。结论：脑血管疾病后遗症可选用活脑灵治疗，但疗程应在３０ｄ以上
Objective: To study the clinical efficacy and safety of live brain-based therapy in the treatment of sequelae of cerebrovascular diseases. Methods: 31 patients diagnosed as cerebrovascular disease (including the primary disease of cerebral hemorrhage and cerebral infarction) sequelae were selected, and their neurological deficits and scores were observed before and after treatment with live brain brain. Results: After 15 days of brain activity, a few cases improved, but the total score of neurological deficit had no significant change (P> 0.05). After 30 days of treatment, the total score of neurological deficit decreased significantly (P <0 .05). Conclusion: Cerebrospinal fluid sequelae can be selected brain activity therapy, but the treatment should be more than 30d